Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Journal of Gastrointestinal Surgery
- Vol. 23 (1) , 101-111
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (T32CA071345, CA140861)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK104956)
This publication has 41 references indexed in Scilit:
- Molecular Link between Liver Fibrosis and Hepatocellular CarcinomaLiver Cancer, 2013
- An improved mouse model that rapidly develops fibrosis in non‐alcoholic steatohepatitisInternational Journal of Experimental Pathology, 2013
- Circulating adiponectin: a potential prognostic marker for hepatocellular carcinomaThe Chinese-German Journal of Clinical Oncology, 2011
- Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesBritish Journal of Pharmacology, 2011
- The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseasesJournal of Advanced Pharmaceutical Technology & Research, 2011
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- 8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancerBritish Journal of Cancer, 2010
- Adiponectin Activates AMP-activated Protein Kinase in Muscle Cells via APPL1/LKB1-dependent and Phospholipase C/Ca2+/Ca2+/Calmodulin-dependent Protein Kinase Kinase-dependent PathwaysJournal of Biological Chemistry, 2009
- Experimental mouse models for hepatocellular carcinoma researchInternational Journal of Experimental Pathology, 2009
- Epidemiology and carcinogenesis of hepatocellular carcinomaHPB, 2005